Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice.

In conclusion, Apa may improve the effective perfusion of tumor vessels and increase the intratumoral distribution of ADR in a certain time window via normalizing tumor vessels. This normalization window (7 to 10 days of treatment) may contribute to develop a regimen of combined medication in clinic use of Apa. PMID: 29977004 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29977004?dopt=Abstract

Source: Acta Pharmacologica Sinica - July 5, 2018 Category: Drugs & Pharmacology Authors: Zhou K, Zhang JW, Wang QZ, Liu WY, Liu JL, Yao L, Cai MM, Ni SY, Cai QY, Wang GJ, Zhou F Tags: Acta Pharmacol Sin Source Type: research